| Title |
Sentinel Lymph Node Biopsy in Thick-Melanoma Patients (N=350): What is Its Prognostic Role?
|
|---|---|
| Published in |
Annals of Surgical Oncology, November 2014
|
| DOI | 10.1245/s10434-014-4211-7 |
| Pubmed ID | |
| Authors |
S. Ribero, S. Osella-Abate, M. Sanlorenzo, E. Balagna, R. Senetta, M.T. Fierro, G. Macripò, L. Macrì, A. Sapino, P. Quaglino |
| Abstract |
Sentinel lymph node biopsy (SLNB) is currently recommended for patients with intermediate-thickness melanomas (T2-T3). Historically, T4 melanoma patients have not been considered good candidates for SLNB because of the high risk of distant progression. However, some authors suggest that T4 melanoma patients could be considered as a heterogeneous group that could benefit from SLNB. |
X Demographics
The data shown below were collected from the profiles of 6 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 3 | 50% |
| Venezuela, Bolivarian Republic of | 1 | 17% |
| Unknown | 2 | 33% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 4 | 67% |
| Practitioners (doctors, other healthcare professionals) | 1 | 17% |
| Scientists | 1 | 17% |
Mendeley readers
The data shown below were compiled from readership statistics for 33 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 33 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 5 | 15% |
| Student > Bachelor | 5 | 15% |
| Researcher | 4 | 12% |
| Student > Doctoral Student | 3 | 9% |
| Other | 3 | 9% |
| Other | 6 | 18% |
| Unknown | 7 | 21% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 19 | 58% |
| Nursing and Health Professions | 2 | 6% |
| Biochemistry, Genetics and Molecular Biology | 1 | 3% |
| Pharmacology, Toxicology and Pharmaceutical Science | 1 | 3% |
| Engineering | 1 | 3% |
| Other | 0 | 0% |
| Unknown | 9 | 27% |
Attention Score in Context
This research output has an Altmetric Attention Score of 7. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 30 January 2019.
All research outputs
#4,742,863
of 23,340,595 outputs
Outputs from Annals of Surgical Oncology
#1,529
of 6,615 outputs
Outputs of similar age
#54,291
of 260,195 outputs
Outputs of similar age from Annals of Surgical Oncology
#10
of 85 outputs
Altmetric has tracked 23,340,595 research outputs across all sources so far. Compared to these this one has done well and is in the 79th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 6,615 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.4. This one has done well, scoring higher than 76% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 260,195 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 78% of its contemporaries.
We're also able to compare this research output to 85 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 89% of its contemporaries.